Cigna
CI · What the business does, what can go wrong, and how options sellers approach it
What it does
The Cigna Group is a US health services company with two main businesses. The first is Evernorth, which includes Express Scripts, a pharmacy benefit manager (PBM), along with specialty pharmacy and other care services. The second is Cigna Healthcare, which sells health insurance and related benefits, mostly to employers, with a smaller international presence.
How it makes money
Evernorth earns money from fees and from the spread on filling prescriptions, negotiating drug prices with manufacturers, and running pharmacy networks for health plans and employers. Specialty pharmacy adds revenue from dispensing high-cost drugs for complex conditions.
Cigna Healthcare earns premiums and fees. Many employer clients self-fund, meaning the employer bears the claims cost and pays Cigna fees to administer the plan. That makes the model less sensitive to claims swings than fully insured coverage.
Why investors own it
- Diversification across pharmacy services and insurance.
- A business tied to steady, recurring demand for healthcare and prescriptions.
- A large employer-focused book, which tends to be sticky.
- Cash generation that the company has historically used for dividends, buybacks and acquisitions.
What can go wrong
- Regulation and politics: PBM practices, drug pricing and rebate rules draw scrutiny from lawmakers and regulators.
- Client concentration: losing a large PBM client or contract can hit results.
- Medical cost trends: higher utilization or expensive new drugs can squeeze margins.
- Integration and deal risk from large acquisitions.
- Competition from other large insurers and PBMs.
What to watch
- Medical care ratio and medical cost trends
- Evernorth adjusted earnings growth and prescription volumes
- Customer retention and contract renewals or losses
- PBM reform legislation and regulatory actions
- Full-year earnings guidance changes
- Capital deployment: buybacks, dividends and acquisitions
Options income angle
Options on CI are typically liquid, with a range of strikes and expirations, though trading is lighter than in the largest mega-cap stocks. Implied volatility tends to rise around quarterly earnings, guidance updates, and headlines about drug pricing or PBM regulation. It can also react to sector moves when peer insurers report.
One caution for premium sellers: policy or regulatory news can cause sharp gaps that skip past your strike. A covered call can cap gains in a sudden rally, and a cash-secured put can leave you owning shares after a steep drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Cigna's 2025 results were reshaped by the March 2025 sale of its Medicare Advantage and related businesses to HCSC, which shrank the insurance side while the pharmacy services side, Evernorth, kept growing. Total revenues were $274,900 million and shareholders' net income was $5,957 million, up 73% mainly because 2024 carried a VillageMD impairment. Management says the move to a rebate-free pharmacy benefit model will weigh on Evernorth's profit over the short term.
How the business did
- Total revenues rose 11% from $247,121 million. Pharmacy revenues rose 17% to $216,672 million on higher prescription utilization from customer growth. Premiums fell 12% to $40,261 million, driven by the HCSC sale.
- Shareholders' net income was $5,957 million versus $3,434 million. Adjusted income from operations, which excludes investment gains and losses, amortization of acquired intangibles and "special items," rose 4% to $8,014 million. Adjusted diluted earnings per share were $29.84 versus $27.33.
- Evernorth's pre-tax adjusted income from operations rose 3% to $7,221 million. Pharmacy Benefit Services fell 2% to $3,506 million, while Specialty and Care Services rose 8% to $3,715 million. Cigna Healthcare fell 2% to $4,153 million. Its medical care ratio (medical costs as a share of premiums) rose to 84.4% from 83.2%, driven by the Individual and Family Plans business.
- Operating cash flow was $9,601 million versus $10,363 million. The company repurchased 11.9 million shares for approximately $3.6 billion, versus 20.9 million shares for approximately $7.0 billion in 2024. It booked $749 million of pre-tax costs for a new strategic optimization program.
Risks specific to this company
- Client contracts: Express Scripts client contracts generally run three years and are open to repricing. Clients can switch easily, and losing a large client or renewing on worse terms could hurt results.
- Rebate-free shift and manufacturers: Drug maker contracts are nonexclusive and can be ended on short notice. The filing says the announced rebate-free model may change how manufacturers deal with the company, and pharmacy benefit reforms could change pricing rules.
- Pharmacy network concentration: More than 65,000 pharmacies participated in its networks, but the 10 largest chains represent approximately 47% of stores in the largest network. A large chain leaving or renegotiating could reduce customer access.
- Legal and regulatory: In February 2026 the company reached a final settlement with the FTC over insulin rebate practices, with no monetary penalty or admission of liability, but it must update some business practices. It also faces litigation claiming it improperly used AI in claims evaluation, and possible indemnification duties tied to audits of the divested Medicare businesses.
- Debt and goodwill: Total indebtedness was approximately $31.5 billion. Goodwill and other intangibles were approximately $73.5 billion, representing 47% of total consolidated assets, so weak performance by acquired businesses could force impairment charges. The VillageMD investment was fully impaired in 2024, a $2.7 billion loss.
- Medical cost estimates: Reserves for unpaid claims rest on judgment, and small misses can move earnings. The Individual and Family Plans business already pushed medical costs higher in 2025.
What management is watching
- Investment and transition costs for the rebate-free pharmacy benefit model, which management expects to affect Evernorth's pre-tax adjusted income from operations over the short term. The company renewed or extended contracts with Evernorth's three largest clients through the end of the decade.
- The strategic optimization program, expected to generate annualized after-tax savings of at least $500 million. Management anticipates future charges.
- Capital expenditures of approximately $1.3 billion in 2026, funded primarily from operating cash flows. Of scheduled long-term debt payments, $2.0 billion relate to 2026.
- Evernorth's key drivers: prescription claim volume, mix of drugs (branded, specialty, generic) and contract affordability improvements.
- Measures management points to: pre-tax adjusted income from operations and adjusted revenues for segments, plus the medical care ratio and SG&A expense ratio for Cigna Healthcare.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed November 5, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
The Cigna Group reported total revenues of $73,683 million, up 6%, but shareholders' net income fell 23% to $1,442 million, mainly because a prior-year gain on selling businesses did not repeat and investment results were lower. Adjusted income from operations, the company's cleaner measure of core earnings, was $2,104 million against $2,096 million a year earlier. Profit fell in the pharmacy benefit business and rose in Cigna Healthcare.
How the business did
- Earnings: For the nine months, total revenues were $213,845 million, up 6%, and shareholders' net income was $4,756 million, up 1%. Adjusted income from operations (which leaves out investment gains and losses, amortization of acquired intangibles and special items) was $6,216 million, versus $5,866 million. Adjusted diluted earnings per share for the quarter were $7.98, versus $7.83.
- Evernorth Health Services: Pre-tax adjusted income was $1,829 million, down 4%. Pharmacy Benefit Services earned $765 million versus $975 million, which the filing attributes mainly to client- and customer-focused initiatives. Specialty and Care Services rose 15% to $1,064 million. Pharmacy claim volume was 546 million, versus 558 million.
- Cigna Healthcare: Pre-tax adjusted income rose 15% to $1,193 million, and adjusted revenues rose 9% to $11,708 million on premium rate increases. The medical care ratio, the share of premiums spent on medical costs, was 85.0% versus 84.8%. Nine-month revenues fell 3% because the company sold its Medicare Advantage and related businesses in the HCSC transaction in March 2025.
- Cash and capital return: Nine-month operating cash flow was $3,281 million versus $3,452 million, with an unfavorable effect from the Inflation Reduction Act cited. The company repurchased 1.8 million shares for approximately $500 million, versus 8.2 million shares for approximately $2.6 billion a year earlier. Debt-to-capitalization was 41.8%, versus 43.0% at December 31, 2025.
- Taxes: The effective tax rate was 19.1% versus 14.0%, as the prior year included tax benefits that did not repeat.
What management is watching
- Accelerate to One: Announced at the September 2026 Investor Day, this multi-year modernization and productivity initiative is meant to generate cost savings through 2030. Management expects to reinvest a portion in growth and innovation, and says the timing and size of savings will vary. The Strategic Optimization Program, a restructuring effort begun in 2025, continues under it.
- Pharmacy benefit contracting: Management points to early renewals of large client contracts, investments to support a rebate-free model, and recontracting tied to affordability and government programs such as the Inflation Reduction Act. It expects these to affect income from operations.
- Individual and Family Plans: The company announced in April 2026 that it will exit this medical business as of January 1, 2027.
- Measures to follow: Management names pre-tax adjusted income from operations and adjusted revenues as its principal measures of segment performance. In Cigna Healthcare it also highlights the medical care ratio and the SG&A expense ratio (selling, general and administrative costs as a share of revenue).
Follow CI in Kortex
The Kortex app shows CI's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.